Smoke-free nicotine is a fast-acting stimulant that briefly and modestly sharpens attention, reaction speed and fine motor control. Gum, patches and lozenges substantially raise smokers' odds of stopping. Larger claims for memory loss, Parkinson's disease and inflamed bowel remain unconfirmed. Habit-forming, it raises heart rate and blood pressure, disturbs sleep, and long use is linked to poorer blood sugar handling. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting Heart Rate | 50–70 bpm | Most sensitive marker of ongoing sympathetic load |
| Blood Pressure | Below 120/80 mmHg | Nicotine raises pressure while present and adds chronic load |
| Fasting Insulin | 2–5 µIU/mL | Earliest signal of the metabolic downside seen in long-term users |
| HOMA-IR | Below 1.0 | Quantifies insulin resistance from the fasting pair |
| HbA1c | 4.8–5.4% | Detects slow drift in glucose control over months |
| hs-CRP | Below 0.5 mg/L | Tracks whether the claimed anti-inflammatory effect appears at all |
| Serum or Salivary Cotinine | No established target for deliberate non-smoker use; tracked against the individual's own pre-use baseline | Confirms actual exposure and detects dose creep the diary misses |
Cadence: Baseline before a first dose; blood pressure and resting heart rate at 1 week and 4 weeks, then every 3–6 months; metabolic panel, inflammation marker and cotinine at 3 months, then every 6–12 months; oral examination every 6 months while any oral format is in use.